杏林製薬の株価時系列
| 日付 | 始値 | 高値 | 安値 | 終値 | 前日比 | 騰落率 | 出来高 |
|---|---|---|---|---|---|---|---|
| 2023/07/21 | 1,747 | 1,751 | 1,738 | 1,751 | +16 | +0.9% | 63,700 |
| 2023/07/20 | 1,747 | 1,751 | 1,732 | 1,735 | -14 | -0.8% | 40,400 |
| 2023/07/19 | 1,746 | 1,749 | 1,735 | 1,749 | +16 | +0.9% | 60,800 |
| 2023/07/18 | 1,713 | 1,734 | 1,713 | 1,733 | +16 | +0.9% | 42,400 |
| 2023/07/14 | 1,718 | 1,724 | 1,706 | 1,717 | +3 | +0.2% | 62,900 |
| 2023/07/13 | 1,719 | 1,722 | 1,704 | 1,714 | +1 | +0.1% | 73,900 |
| 2023/07/12 | 1,708 | 1,717 | 1,706 | 1,713 | +10 | +0.6% | 79,600 |
| 2023/07/11 | 1,730 | 1,732 | 1,700 | 1,703 | -16 | -0.9% | 79,400 |
| 2023/07/10 | 1,722 | 1,727 | 1,714 | 1,719 | -3 | -0.2% | 82,200 |
| 2023/07/07 | 1,728 | 1,735 | 1,718 | 1,722 | -6 | -0.3% | 148,900 |
| 2023/07/06 | 1,749 | 1,750 | 1,715 | 1,728 | -20 | -1.1% | 130,100 |
| 2023/07/05 | 1,728 | 1,750 | 1,727 | 1,748 | +16 | +0.9% | 68,400 |
| 2023/07/04 | 1,745 | 1,751 | 1,732 | 1,732 | -29 | -1.6% | 105,300 |
| 2023/07/03 | 1,755 | 1,772 | 1,754 | 1,761 | +10 | +0.6% | 59,800 |
| 2023/06/30 | 1,757 | 1,758 | 1,740 | 1,751 | -5 | -0.3% | 85,500 |
| 2023/06/29 | 1,766 | 1,775 | 1,751 | 1,756 | -11 | -0.6% | 68,800 |
| 2023/06/28 | 1,748 | 1,767 | 1,746 | 1,767 | +19 | +1.1% | 80,900 |
| 2023/06/27 | 1,758 | 1,760 | 1,735 | 1,748 | -20 | -1.1% | 76,900 |
| 2023/06/26 | 1,780 | 1,781 | 1,756 | 1,768 | -5 | -0.3% | 80,200 |
| 2023/06/23 | 1,788 | 1,788 | 1,767 | 1,773 | -11 | -0.6% | 119,700 |
| 2023/06/22 | 1,768 | 1,787 | 1,768 | 1,784 | +16 | +0.9% | 92,600 |
| 2023/06/21 | 1,772 | 1,786 | 1,766 | 1,768 | +4 | +0.2% | 124,000 |
| 2023/06/20 | 1,757 | 1,764 | 1,748 | 1,764 | ±0 | ±0% | 45,400 |
| 2023/06/19 | 1,759 | 1,771 | 1,752 | 1,764 | +7 | +0.4% | 57,400 |
| 2023/06/16 | 1,738 | 1,759 | 1,737 | 1,757 | +16 | +0.9% | 202,700 |
| 2023/06/15 | 1,734 | 1,748 | 1,733 | 1,741 | +3 | +0.2% | 83,200 |
| 2023/06/14 | 1,748 | 1,748 | 1,733 | 1,738 | -8 | -0.5% | 81,900 |
| 2023/06/13 | 1,750 | 1,759 | 1,741 | 1,746 | ±0 | ±0% | 99,200 |
| 2023/06/12 | 1,748 | 1,753 | 1,735 | 1,746 | +7 | +0.4% | 86,600 |
| 2023/06/09 | 1,751 | 1,751 | 1,733 | 1,739 | +2 | +0.1% | 139,300 |
| 2023/06/08 | 1,735 | 1,744 | 1,725 | 1,737 | +10 | +0.6% | 97,300 |
| 2023/06/07 | 1,741 | 1,753 | 1,723 | 1,727 | -19 | -1.1% | 113,500 |
| 2023/06/06 | 1,733 | 1,746 | 1,717 | 1,746 | +9 | +0.5% | 115,400 |
| 2023/06/05 | 1,733 | 1,758 | 1,725 | 1,737 | -36 | -2% | 207,600 |
| 2023/06/02 | 1,749 | 1,773 | 1,747 | 1,773 | +30 | +1.7% | 91,800 |
| 2023/06/01 | 1,750 | 1,762 | 1,740 | 1,743 | +12 | +0.7% | 104,000 |
| 2023/05/31 | 1,751 | 1,760 | 1,718 | 1,731 | -33 | -1.9% | 376,300 |
| 2023/05/30 | 1,782 | 1,782 | 1,756 | 1,764 | -22 | -1.2% | 60,700 |
| 2023/05/29 | 1,780 | 1,799 | 1,769 | 1,786 | +27 | +1.5% | 82,300 |
| 2023/05/26 | 1,793 | 1,793 | 1,758 | 1,759 | -36 | -2% | 72,100 |
| 2023/05/25 | 1,786 | 1,808 | 1,781 | 1,795 | +9 | +0.5% | 127,300 |
| 2023/05/24 | 1,795 | 1,796 | 1,782 | 1,786 | -4 | -0.2% | 104,100 |
| 2023/05/23 | 1,784 | 1,794 | 1,779 | 1,790 | +14 | +0.8% | 177,900 |
| 2023/05/22 | 1,747 | 1,778 | 1,746 | 1,776 | +35 | +2% | 66,800 |
| 2023/05/19 | 1,755 | 1,755 | 1,735 | 1,741 | -4 | -0.2% | 66,300 |
| 2023/05/18 | 1,770 | 1,770 | 1,742 | 1,745 | -17 | -1% | 64,300 |
| 2023/05/17 | 1,763 | 1,769 | 1,756 | 1,762 | -4 | -0.2% | 57,800 |
| 2023/05/16 | 1,750 | 1,766 | 1,745 | 1,766 | +22 | +1.3% | 89,400 |
| 2023/05/15 | 1,740 | 1,749 | 1,737 | 1,744 | +11 | +0.6% | 64,100 |
| 2023/05/12 | 1,730 | 1,740 | 1,723 | 1,733 | +13 | +0.8% | 88,100 |
201～
250
件表示中 / 3457件
類似銘柄と比較する
現在ご覧いただいている「杏林製薬」と類似性の高い銘柄をピックアップ。投資家が注目しているデータで比較できるようになっています。銘柄選びの参考情報としてご活用ください。
| 銘柄名 | 最低購入代金 | 売上高 成長率 |
経常 増益率 |
配当 利回り |
PER | PBR | 直近のチャート | 特色 |
|---|---|---|---|---|---|---|---|---|
| 杏林製薬 | 171,500円 | +3.2% | +4.5% | 3.03% | 19.70倍 | 0.75倍 |
|
医薬中堅。柱のぜんそく薬、呼吸器アレルギー薬は下期に比重。消化器領域育成。後発品も |
| 持田薬 | 304,500円 | +3.0% | +27.5% | 2.63% | 19.28倍 | 0.85倍 |
|
医薬中堅。高脂血症薬、降圧薬など循環器系得意。婦人科系にも強み。消化器系育成。化粧品も |
| 鳥居薬 | 385,000円 | +7.3% | +16.8% | 3.12% | 23.03倍 | 0.90倍 |
|
ＪＴ傘下。自社製品の腎・透析、アレルゲン等の開発強化。柱の抗ＨＩＶ薬の販売権喪失が直撃 |
| ジーエヌアイ | 234,700円 | +52.1% | +23.3% | 0.00% | 16.58倍 | 3.46倍 |
|
創薬ベンチャー。米国で人工骨も。中国の特発性肺線維症薬で高シェア、米中に研究開発機能 |
| ゼリア新薬 | 200,100円 | +9.6% | +17.5% | 2.30% | 11.30倍 | 1.11倍 |
|
製薬中堅。医療用は消化器系中心。滋養強壮剤「ヘパリーゼ」も柱。スイス企業買収で海外展開 |
市場注目の銘柄
チャート関連のコラム
